Zosano Pharma Corporation (ZSAN)

NASDAQ: ZSAN · IEX Real-Time Price · USD
0.505 -0.025 (-4.70%)
Jan 18, 2022 10:56 AM EST - Market open

Company Description

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system.

Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Zosano Pharma Corporation
Zosano Pharma Logo
CountryUnited States
Founded2006
IPO DateJan 27, 2015
IndustryHealth Care Equipment & Supplies
SectorHealth Care
Employees45
CEOSteven Lo

Contact Details

Address:
34790 Ardentech Ct
Fremont, California 94555-3657
United States
Phone510 745 1200
Websitezosanopharma.com

Stock Details

Ticker SymbolZSAN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001587221

Key Executives

NamePosition
Steven LoSenior Vice President of Operations, President, Chief Executive Officer and Director
Dr. Donald J. KellermanVice President of Clinical Development and Medical Affairs
Christine MatthewsChief Financial Officer
Lu LiuVice President of Technical Operations
Jeffrey L. QuillenSecretary
Kristina WargaVice President and Corporate Controller

Latest SEC Filings

DateTypeTitle
Jan 5, 20228-KCurrent report
Dec 13, 20218-KCurrent report
Dec 9, 20214Statement of changes in beneficial ownership of securities
Dec 9, 20213Initial statement of beneficial ownership of securities
Nov 30, 20218-KCurrent report
Nov 24, 20214Statement of changes in beneficial ownership of securities
Nov 17, 20218-KCurrent report
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 10, 20218-KCurrent report
Oct 29, 20218-KCurrent report
View All SEC Filings